G A T C G A T C G A T C G A T C G A T C G A T C G A T C G A T C G A T C G A T C G A T C G A T C G A T C G A T C G A T C

QIAGEN
Financial Report 2017

  • Solid 2017 performance as QIAGEN moving ahead on a new growth trajectory
  • Group adjusted net sales rise 6% at constant exchange rates (CER) to $1.42 billion
  • Adjusted operating income grows 14% to $371.5 million
  • Adjusted diluted EPS of $1.27 per share vs. $1.11 in 2016
  • Free cash flow of $196.7 million, impacted by $89 million of restructuring and litigation settlement payments
  • Sustaining growth trajectory toward 2020 goals with Sample to Insight portfolio

Our Mission

As the innovative market and technology leader, QIAGEN creates Sample to Insight solutions that enable access to valuable molecular insights from any biological sample.

Read more

Overview

QIAGEN Insights Magazine

To the magazine

Report of the Supervisory Board

Read more

The Executive Committee

Read more

Common Shares

Read more

Management Report

Business and Operating Environment

Read more

Opportunities and Risks

Read more

Performance Review

Read more

Human Resources

Read more

Non-Financial Statement

Read more

Future Perspectives

Read more

Corporate Governance and Compensation

Overview

Read more

Managing Board

Read more

Supervisory Board

Read more

Share Ownership

Read more

Additional Information

Read more

Financial Results

Consolidated Financial Statements

Read more

Notes to Consolidated Financial Statements

Read more

Auditor’s Reports

Read more

List of Subsidiaries

Read more

Appendix

Service

Read more

Downloads

  • Financial Report 2017 – Complete
    7.9MB PDF
    Download
  • Financial Report 2017 – Overview
    2.6MB PDF
    Download
  • Financial Report 2017 – Management Report
    2.8MB PDF
    Download
  • Financial Report 2017 – Corporate Governance and Compensation
    765KB PDF
    Download
  • Financial Report 2017 – Financial Results
    1.8MB PDF
    Download
  • Financial Report 2017 – Service
    41KB PDF
    Download